Aethlon Medical Incorporated (NASDAQ:AEMD)’s Stock Is Buy After Less Market Selling

June 20, 2017 - By Nellie Frank

 Aethlon Medical Incorporated (NASDAQ:AEMD)'s Stock Is Buy After Less Market Selling

The stock of Aethlon Medical Incorporated (NASDAQ:AEMD) registered a decrease of 27.78% in short interest. AEMD’s total short interest was 141,700 shares in June as published by FINRA. Its down 27.78% from 196,200 shares, reported previously. With 36,100 shares average volume, it will take short sellers 4 days to cover their AEMD’s short positions. The short interest to Aethlon Medical Incorporated’s float is 2.43%.

About 4,955 shares traded. Aethlon Medical, Inc. (NASDAQ:AEMD) has declined 56.57% since June 20, 2016 and is downtrending. It has underperformed by 73.27% the S&P500.

Aethlon Medical, Inc. is a medical device firm focused on creating devices for cancer, infectious disease and other life-threatening conditions. The company has market cap of $15.99 million. The Firm operates through two divisions: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. It currently has negative earnings. The Company’s lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression.

More notable recent Aethlon Medical, Inc. (NASDAQ:AEMD) news were published by: which released: “Aethlon Medical Inc.: Total Scam Or Legit Company?” on December 08, 2014, also with their article: “News Aethlon Medical Inc.AEMD” published on February 17, 2013, published: “2.01” on April 19, 2011. More interesting news about Aethlon Medical, Inc. (NASDAQ:AEMD) were released by: and their article: “Aethlon Medical Discloses Hemopurifier┬« Clinical Trial and Manufacturing …” published on March 31, 2016 as well as‘s news article titled: “Aethlon Medical Announces Health Canada Approval of Ebola Treatment Protocol” with publication date: May 13, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.